Renovorx announces clinical data abstract at the 2024 society of interventional radiology annual scientific meeting

Los altos, calif.--(business wire)--renovorx, inc. (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the acceptance of a clinical data abstract for the 2024 society of interventional radiology (sir) annual scientific meeting, held march 23-28 in salt lake city, utah. the abstract will highlight the company's lead product candidate, renovogem, and proprietary trans-arterial micro-perfu.
RNXT Ratings Summary
RNXT Quant Ranking